Printer Friendly

MEAD JOHNSON LABS' OVCON(R) GOES 'GREEN'; LEADING ORAL CONTRACEPTIVE IS FIRST IN PRODUCT PORTFOLIO TO ADOPT ENVIRONMENTALLY SAFE PACKAGING

 PRINCETON, N.J., Oct. 12 /PRNewswire/ -- Mead Johnson Laboratories announced today that its leading oral contraceptive will change its packaging to environmentally conscious materials. Starting immediately, the packaging for OVCON(R) (norethindrone and ethinyl estradiol tablets, USP) will be made from recycled and recyclable products.
 The switch of OVCON to "green" packaging is the first step in an ongoing process that eventually will convert all Mead Johnson Laboratories' products to environmentally responsible packaging.
 "Women and their physicians, especially gynecologists, have indicated a preference for recyclable product packaging," said Tom Ludlam, Jr., vice president, general manager, Mead Johnson Laboratories.
 "We have taken a major step in our switch of OVCON packaging to meet the needs and preferences of our customers. This move is in keeping with our long-standing commitment to quality products and customer satisfaction," Ludlam said.
 According to Population Action International, 19 million women use oral contraceptives. The packaging, which is often made of plastic and foil, is discarded every month and this is a cause for concern to many.
 OVCON's outside box and interior labeling are now made of a combination of 50 percent recycled paperboard and a minimum of 20 to 30 percent post-consumer paper waste. The recycled paper comes from remnants of the paper-making process which would have otherwise been discarded. The pill dispenser will now be made of recyclable plastic, which can be safely discarded by women who live in communities where separation of recyclables is available.
 OVCON(R) 50 and OVCON(R) 35 provide a continuous regimen for oral contraception. OVCON 50 contains 1 mg of norethindrone and .05 mg of ethinyl estradiol. OVCON 35 contains only 0.4 mg of norethindrone and .035 mg of ethinyl estradiol.
 Oral contraceptives are indicated for the prevention of pregnancy and are highly effective when taken correctly, with a failure rate of about 1 percent per year when used without missing any pills. The most common side effects of all oral contraceptives are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness and difficulty wearing contact lenses. These side effects, especially nausea and vomiting, usually subside within the first three months of use. Other serious and minor side effects have been reported.
 In addition to OVCON(R) 50 and OVCON(R) 35 (norethindrone and ethinyl estradiol tablets, USP), Mead Johnson Laboratories, a Bristol- Myers Squibb company, also markets ESTRACE(R) (estradiol tablets, USP), an estrogen replacement therapy; VAGISTAT(R)-1 (tioconazole), a vaginal ointment for vaginal yeast infections; NATALINS(R)RX, multivitamin and multimineral supplement with beta-carotene; and STADOL(R)NS(TM) (butorphanol tartrate), a nasal spray analgesic.
 Bristol-Myers Squibb Company (NYSE: BMY) is a diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals, and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies and diagnostic agents.
 /delval/
 -0- 10/12/93
 /CONTACT: Patrick Donohue of Bristol-Myers Squibb Company, 609-252-5685, or Lisa Weiss of Brown and Powers, 212-922-1200, for Bristol-Myers Squibb/
 (BMY)


CO: Mead Johnson Laboratories; Bristol-Myers Squibb Company ST: New Jersey IN: MTC SU:

MP-MK -- PH010 -- 1066 10/12/93 11:49 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 12, 1993
Words:521
Previous Article:ALLIED WASTE INDUSTRIES, INC. ANNOUNCES RELOCATION OF CORPORATE OFFICE
Next Article:BOEING DOUBLES NUMBER OF FIELD-SERVICE BASES IN CHINA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters